Literature DB >> 24324918

The Motivations and Experiences of Young Women in a Microbicide Trial in the USA and Puerto Rico.

Rebecca Giguere1, Gregory D Zimet, Jessica A Kahn, Curtis Dolezal, Cheng-Shiun Leu, Marina Mabragaña, Ian McGowan, Alex Carballo-Diéguez.   

Abstract

Young women are an important target group in microbicide research, yet little is known about why they participate and stay in microbicide trials. Our study examined motivations for participating in a Phase I microbicide trial among 61 women ages 18 - 24 years in the continental USA and Puerto Rico. We also examined their perspectives on study participation. Participants underwent a semi-structured in-depth interview in which they were asked about factors that motivated enrollment and their experiences while participating. They also completed a Web-based Computer Assisted Self Interview in which they were asked to rate study burden (1 = low to 4 = high). Factors that motivated enrollment were altruism (29%), compensation (17%), a combination of altruism and compensation (37%) and free medical exams (17%). Factors that encouraged participants to stay in the study were study staff (95%), confirmation of good health (41%), and the opportunity to learn about their bodies (17%). Mean ratings of study burden ranged from 1.83 (having to travel to site) to 2.41 (colposcopy), indicating that participants were not highly bothered by visits or procedures. Although Phase I trials require invasive procedures, participants were not highly bothered by them and recognized them as necessary. Good relationships with staff and clear information about how procedures contribute to study goals may encourage participants to remain in trials. Young women may be motivated to enter microbicide trials by stressing the role they will play in discovering better HIV-prevention methods and highlighting the comprehensive preventive exams they will receive.

Entities:  

Keywords:  HIV; Microbicides; Motivation; Puerto Rico; Research Participation; USA; Young Women

Year:  2013        PMID: 24324918      PMCID: PMC3855411          DOI: 10.4236/wja.2013.33023

Source DB:  PubMed          Journal:  World J AIDS        ISSN: 2160-8814


  25 in total

1.  Forging convictions: the effects of active participation in a clinical trial.

Authors:  Clare Scott; Jan Walker; Peter White; George Lewith
Journal:  Soc Sci Med       Date:  2011-05-18       Impact factor: 4.634

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda.

Authors:  Eugene Ruzagira; Symon Wandiembe; Leonard Bufumbo; Jonathan Levin; Matthew A Price; Heiner Grosskurth; Anatoli Kamali
Journal:  Trop Med Int Health       Date:  2009-01-15       Impact factor: 2.622

4.  Ethics in human subjects research: do incentives matter?

Authors:  Ruth W Grant; Jeremy Sugarman
Journal:  J Med Philos       Date:  2004-12

5.  Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial.

Authors:  Jacqueline M O'Connell; Robert S Hogg; Keith Chan; Steffanie A Strathdee; Nancy McLean; Steve L Martindale; Brian Willoughby; Robert Remis
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-15       Impact factor: 3.731

6.  Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).

Authors:  Ian McGowan; Kailazarid Gomez; Karen Bruder; Irma Febo; Beatrice A Chen; Barbra A Richardson; Marla Husnik; Edward Livant; Clare Price; Cindy Jacobson
Journal:  AIDS       Date:  2011-05-15       Impact factor: 4.177

7.  Women's willingness to participate in microbicide trials in Northern Thailand.

Authors:  K Tharawan; C Manopaiboon; C Ellertson; K Limpakarnjanarat; S Chaikummao; P H Kilmarx; K Blanchard; C Coggins; T D Mastro; C Elias
Journal:  J Acquir Immune Defic Syndr       Date:  2001-10-01       Impact factor: 3.731

8.  Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities.

Authors:  R P Strauss; S Sengupta; S Kegeles; E McLellan; D Metzger; S Eyre; F Khanani; C B Emrick; K M MacQueen
Journal:  J Acquir Immune Defic Syndr       Date:  2001-01-01       Impact factor: 3.731

9.  A Review of Paying Research Participants: It's Time to Move Beyond the ethical Debate.

Authors:  Elizabeth B D Ripley
Journal:  J Empir Res Hum Res Ethics       Date:  2006-12       Impact factor: 1.742

10.  Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider.

Authors:  Elizabeth R Volkmann; Deon Claiborne; Judith S Currier
Journal:  HIV Clin Trials       Date:  2009 Mar-Apr
View more
  3 in total

1.  Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women.

Authors:  Rebecca Pellett Madan; Charlene S Dezzutti; Lorna Rabe; Sharon L Hillier; Jeanne Marrazzo; Ian McGowan; Barbra A Richardson; Betsy C Herold
Journal:  Am J Reprod Immunol       Date:  2015-06-26       Impact factor: 3.886

2.  Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana.

Authors:  Lauren Toledo; Eleanor McLellan-Lemal; Faith L Henderson; Poloko M Kebaabetswe
Journal:  World J AIDS       Date:  2015-02-12

3.  Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.

Authors:  Ariana W K Katz; Barbara S Mensch; Kubashni Woeber; Petina Musara; Juliane Etima; Ariane van der Straten
Journal:  BMC Womens Health       Date:  2019-01-25       Impact factor: 2.809

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.